Drug intelligence / Profile preview

HDM2022

Development stage: Preclinical
Lead developer: Huadong Medicine
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

HDM2022 is an orally bioavailable small molecule GSPT1 molecular glue degrader (MGD) being developed by Huadong Medicine for the treatment of MYC-driven tumors. It works by selectively inducing the degradation of the GSPT1 protein, which is essential for protein translation termination and is often a vulnerability in tumors with high MYC expression. Preclinical data presented at the 2025 AACR Annual Meeting demonstrated its potency and selectivity in tumor models.

Targets

GSPT1 (G1 to S phase transition 1)

Beyond the preview

Go deeper on HDM2022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HDM2022.

Explore the full profile